TCGA-49-4490-01A-21R-1858-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 45
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- COAGULATION+0.410
- MYOGENESIS+0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.350
- KRAS_SIGNALING_DN+0.330
- ANGIOGENESIS+0.270
- HEDGEHOG_SIGNALING+0.260
- KRAS_SIGNALING_UP+0.260
- APICAL_JUNCTION+0.220
- NOTCH_SIGNALING+0.200
- PANCREAS_BETA_CELLS+0.140
Top 10 suppressed
- E2F_TARGETS-0.670
- G2M_CHECKPOINT-0.600
- MYC_TARGETS_V1-0.430
- UNFOLDED_PROTEIN_RESPONSE-0.430
- MITOTIC_SPINDLE-0.420
- MTORC1_SIGNALING-0.410
- PROTEIN_SECRETION-0.400
- PI3K_AKT_MTOR_SIGNALING-0.370
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.330
- DNA_REPAIR-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-97-8547-01A-11R-2403-07 | — | cohortA1 | 0.896 |
| 2 | TCGA-XF-A9SP-01A-11R-A39I-07 | — | — | 0.895 |
| 3 | TCGA-49-4512-01A-21R-1858-07 | — | cohortA1 | 0.893 |
| 4 | s0095205 | — | — | 0.881 |
| 5 | X9cad7a78.ea9b.47b0.9d06.e5e696031cc3 | — | cohortA1 | 0.870 |
| 6 | TCGA-55-8096-01A-11R-2241-07 | — | cohortA1 | 0.870 |
| 7 | TCGA-ZF-A9R9-01A-11R-A38B-07 | — | — | 0.865 |
| 8 | SRR1487825 | GTEX | — | 0.861 |
| 9 | SRR1378155 | GTEX | — | 0.861 |
| 10 | TCGA-XF-A8HH-01A-11R-A38B-07 | — | — | 0.858 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| COAGULATION | 0.410 | Binimetinib | — uncovered |
| MYOGENESIS | 0.360 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.350 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.330 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.270 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.260 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.260 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.220 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.140 | Cobimetinib | — uncovered |
| GLYCOLYSIS | 0.120 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.080 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.060 | Inavolisib | — uncovered |
| HYPOXIA | 0.030 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.020 | Inavolisib | — uncovered |